

PTO-1449 REPRODUCED

**INFORMATION DISCLOSURE CITATION
IN AN APPLICATION**

(Use several sheets if necessary)

ATTORNEY DOCKET NO.
GG119.2US

APPLICATION NO.
Unassigned

APPLICANT
Carl Risinger et al.

FILING DATE
August 30, 2001

GROUP
Unassigned

11040 U.S. PTO
09/943531
08/30/01

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
46	AA	5,912,120	15-Jun-1999	Goldstein et al.	435	6	
46	AB	5,786,191	28-Jul-1998	Goldstein et al.	435	189	
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						

EXPRESS MAIL NO. EK748827470US

FOREIGN PATENT DOCUMENTS

EXAM INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
46	AI	WO 00/12757	25-Aug-1999	Hauzenberger	C12Q 1/68		
	AJ						
	AK						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)


	AL	
	AM	
	AN	
	AO	
	AP	

EXAMINER

Smith

DATE CONSIDERED

9/22/05



PTO/SB/08 (2-92)

Sheet 1 of 1

Form PTO-449

Docket Number 532592002000

Application Number 09/943,531

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Applicant

Carl RISINGER, et al.

Filing Date August 30, 2001

Group Art Unit 1635

Mailing Date August 25, 2003

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
DUP LIC.	1.	07/1998	5,786,191	Goldstein, et al.	435	189	DUPLICATE
DUP LIC.	2.	06/1999	5,912,120	Goldstein, et al.	435	6	DUPLICATE

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
hjt	3.	11/1995	WO 95/30766	✓ PCT			
	4.	03/2000	WO 00/12757	✓ PCT			
hjt	5.	07/2002	PCT/GB01/00828	GB			

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
hjt	6.	Database EMBL "Online! retrieved from EMBL, Accession no.AR071577 (Abstract)
	7.	Excoffier, et al. (1995) Mol Biol Evol 12:921-927
	8.	Karam, W.G. et al. (1996) Drug Metabolism and Disposition 24(10):1081-1087
	9.	Kim, M.J. et al. (2001) Clinical Pharmacology & Therapeutics 69(2):P39
hjt	10.	http://www.imm.ki.se/cypalleles/for listing (printed 08/18/03)

EXAMINER:

DATE CONSIDERED:

9/22/05

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A(08-03)
Approved for use through 07/01/2008, OMB 0551-0031
U.S. Patent & Trademark Office: U.S. DEPARTMENT OF COMMERCE

Complete if Known

Application Number	09/943,531
Filing Date	08/30/2001
First Named Inventor	RISINGER
Group Art Unit	1634
Examiner Name	SAKELARIS, SALLY A

Sheet 1 of 3

Attorney Docket No: SGL-2020-UT

US PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1.	4,656,127	04/07/1987	MUNDY	DUPLICATE IDS
	A2.	4,683,195	07/28/1987	MULLIS and ERLICH	
	A3.	4,683,202	07/28/1987	MULLIS	NOT CONSIDERED
	A4.	4,851,331	07/25/1989	VARY and DIAMOND	
	A5.	4,965,188	10/23/1990	MULLIS and ERLICH	See 8/10/05 IDS!
	A6.	5,547,835	08/20/1996	KOESTER	
	A7.	5,605,798	02/25/1997	KOESTER	
	A8.	5,679,524	10/21/1997	NIKIFOROV and KARN	
	A9.	5,691,141	11/25/1997	KOESTER	
	A10.	5,834,189	11/10/1998	STEVENS and DUNN	
	A11.	5,849,542	12/15/1998	REEVE and HOWE	
	A12.	5,851,770	12/22/1998	BABON and YOUIL	
	A13.	5,869,242	02/09/1998	KAMB	
	A14.	5,876,934	03/02/1999	DUTHIE and SEVIGNY	
	A15.	5,891,625	04/06/1999	BUCHARDT and EGHOLM	
	A16.	5,908,755	06/01/1999	KUMAR and HEANEY	
	A17.	5,912,118	06/15/1999	ANSORGE and VOSS	
	A18.	5,928,906	07/27/1999	KOESTER and VAN DEN BOOM	
	A19.	5,952,174	09/14/1999	NIKIFOROV and KARN	
	A20.	5,958,692	09/28/1999	COTTON and YOUIL	

EXAMINER

NOT CONSIDERED


DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)
 * EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional) : Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Sheet 2 of 3

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A(03-03)
Approved for use through 07/31/2008, OMB 0531-0031
US Patent & Trademark Office, U.S. DEPARTMENT OF COMMERCE**Complete if Known**

Application Number	09/943,531
Filing Date	08/30/2001
First Named Inventor	RISINGER
Group Art Unit	1634
Examiner Name	SAKELARIS, SALLY A

Attorney Docket No: SGL-2020-UT

US PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A21.	5,976,802	11/02/1999	ANSORGE and VOSS	
	A22.	5,981,186	11/09/1999	GABE and GILCHRIST	
	A23.	5,998,143	12/07/1999	ELLIS and DODGE	
	A24.	6,004,744	12/21/1999	GOELET and KNAPP	
	A25.	6,013,431	01/11/2000	SOEDERLUND and SYVANEN	
	A26.	6,013,499	01/11/2000	NARUMIYA and IWAMATSU	
	A27.	6,017,702	01/25/2000	LEE and ROSENBLUM	
	A28.	6,043,031	03/28/2000	KOESTER and HIGGENS	
	A29.	6,046,005	04/04/2000	JU and KONRAD	
	A30.	6,087,095	07/11/2000	ROSENTHAL and BRENNER	
	A31.	6,110,684	08/29/2000	KEMPER and BIRKENKAMP-DEMTHOEDER	
	A32.	6,183,958	02/06/2001	STANTON	
	A33.	6,194,144	02/27/2001	KOESTER	
	A34.	6,210,891	04/03/2001	NYREN and UHLEN	
	A35.	6,229,911	05/08/2001	BALABAN and AGGARWAL	
	A36.				
	A37.				
	A38.				

*DUPLICATE
REFERENCES*

FOREIGN PATENT DOCUMENTS

EXAMINER

NOT CONSIDERED

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A(08-03)

Approved for use through 07/31/2008. OMB 0551-0021

US Patent & Trademark Office: U.S. DEPARTMENT OF COMMERCE

Sheet 3 of 3

Complete if Known

Application Number	09/943,531
Filing Date	08/30/2001
First Named Inventor	RISINGER
Group Art Unit	1634
Examiner Name	SAKELARIS, SALLY A

Attorney Docket No: SGL-2020-UT

Examiner Initials*	Cite No. ¹	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
	A39	WO0120039	03/22/2001	ROTHBERG and BADER	Not Considered	
	A40	WO0127326	04/19/2001	EGHOLM and CHEN	Duplicate References	
	A41	WO0127327	04/19/2001	BRENNAN and CHATELAIN	from 8/10/05 IDS	
	A42	WO0127329	04/19/2001	MACLEOD and ALDAZ		
	A43					
	A44					

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS


Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A45	ANDERSON et al., Pharmacogenetics, 2(1):25-31 (1992)	
	A46	BALIAN et al., Clin. Pharmacol. Ther., 57(6):662-669 (1995)	Not Considered IDS
	A47	BERTILSSON, Clin. Pharmacokinet., 29(3):192-209 (1995)	Duplicated
	A48	SHANG et al., Br. J. clin. Pharmac., 39:511-518 (1995)	8/10/05
	A49	EVANS et al., Pharmacogenetics, 5(2):64-71 (1995)	
	A50	GOLDSTEIN et al., Biochemistry, 33(7):1743-1752 (1994)	
	A51	GOLDSTEIN et al., Pharmacogenetics, 7(1):59-64 (1997)	
	A52	GOLDSTEIN, Br. J. clin. Pharmac., 52:349-355 (2001)	
	A53	IBEANU et al., J. Pharmacol. Exp. Ther., 290(2):635-640 (1999)	
	A54	IEIRI et al., Clin. Pharmacol. Ther., 59(6):647-653 (1996)	
	A55	MACAULAY et al., Science, 308:1034-1036 (2005)	
	A56	MEYER and ZANGER, Annu. Rev. Pharmacol. Toxicol., 37:269-296 (1997)	
	A57	RICHARDS et al., Am. J. Hum. Genet. 67:1251-1276 (2000)	
	A58	TANAKA, J Clin Pharm Ther., 24:323-329 (1999)	
	A59	WILKINSON et al., Pharmac. Ther. 43:53-76 (1989)	
	A60	YIN et al., J. Clin. Pharmacol. 44:582-589 (2004)	
	A61		
	A62		

EXAMINER

DATE CONSIDERED

Substituted Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached



Approved for use through 07/31/2008. OIG 005-1-0021
US Patent & Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	09/943,531
Filing Date	08/30/2001
First Named Inventor	RISINGER
Group Art Unit	1634
Examiner Name	SAKELARIS, SALLY A

Sheet 1 of 3

Attorney Docket No: SGL-2020-UT

US PATENT DOCUMENTS

Examiner Initials *	Cite No. 1	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1.	4,656,127	04/07/1987	MUNDY	
	A2.	4,683,195	07/28/1987	MULLIS and ERLICH	
	A3.	4,683,202	07/28/1987	MULLIS	
	A4.	4,851,331	07/25/1989	VARY and DIAMOND	
	A5.	4,965,188	10/23/1990	MULLIS and ERLICH	
	A6.	5,547,835	08/20/1996	KOESTER	
	A7.	5,605,798	02/25/1997	KOESTER	
	A8.	5,679,524	10/21/1997	NIKIFOROV and KARN	
	A9.	5,691,141	11/25/1997	KOESTER	
	A10.	5,834,189	11/10/1998	STEVENS and DUNN	
	A11.	5,849,542	12/15/1998	REEVE and HOWE	
	A12.	5,851,770	12/22/1998	BABON and YOUIL	
	A13.	5,869,242	02/09/1998	KAMB	
	A14.	5,876,934	03/02/1999	DUTHIE and SEVIGNY	
	A15.	5,891,625	04/06/1999	BUCHARDT and EGHOLM	
	A16.	5,908,755	08/01/1999	KUMAR and HEANEY	
	A17.	5,912,118	08/15/1999	ANSORGE and VOSS	
	A18.	5,928,906	07/27/1999	KOESTER and VAN DEN BOOM	
	A19.	5,952,174	09/14/1999	NIKIFOROV and KARN	
	A20.	5,958,692	09/28/1999	COTTON and YOUIL	


EXAMINER

DATE CONSIDERED

9/22/05

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional) : Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO
**INFORMATION DISCLOSURE
 STATEMENT BY APPLICANT**
 (Use as many sheets as necessary)




Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it carries a valid OMB control number.
 Approved for use through 07/01/2008, OMB 0551-0051
 US Patent & Trademark Office, U.S. DEPARTMENT OF COMMERCE

Complete if Known

Application Number	09/943,531
Filing Date	08/30/2001
First Named Inventor	RISINGER
Group Art Unit	1634
Examiner Name	SAKELARIS, SALLY A
Attorney Docket No:	SGL-2020-UT

Sheet 2 of 3

US PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A21.	5,976,802	11/02/1999	ANSORGE and VOSS	
	A22.	5,981,186	11/09/1999	GABE and GILCHRIST	
	A23.	5,998,143	12/07/1999	ELLIS and DODGE	
	A24.	6,004,744	12/21/1999	GOELET and KNAPP	
	A25.	6,013,431	01/11/2000	SOEDERLUND and SYVANEN	
	A26.	6,013,499	01/11/2000	NARUMIYA and IWAMATSU	
	A27.	6,017,702	01/25/2000	LEE and ROSENBLUM	
	A28.	6,043,031	03/28/2000	KOESTER and HIGGENS	
	A29.	6,046,005	04/04/2000	JU and KONRAD	
	A30.	6,087,095	07/11/2000	ROSENTHAL and BRENNER	
	A31.	6,110,684	08/29/2000	KEMPER and BIRKENKAMP-DEMTROEDER	
	A32.	6,183,958	02/06/2001	STANTON	
	A33.	6,194,144	02/27/2001	KOESTER	
	A34.	6,210,891	04/03/2001	NYREN and UHLEN	
	A35.	6,229,911	05/08/2001	BALABAN and AGGARWAL	
	A36.				
	A37.				
	A38.				

FOREIGN PATENT DOCUMENTS


EXAMINER

DATE CONSIDERED

9/22/05

Substitute Disclosure Statement Form (PTO-144B)
 * EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 800. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO
**INFORMATION DISCLOSURE
 STATEMENT BY APPLICANT**
 (Use as many sheets as necessary)



Under the Privacy Protection Act of 1974, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Application Number 09/943,531
 Filing Date 08/30/2001
 First Named Inventor RISINGER
 Group Art Unit 1634
 Examiner Name SAKELARIS, SALLY A

Sheet 3

Attorney Docket No: SGL-2020-UT

Examiner Initials*	Cite No.	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
S	A39.	WO0120039	03/22/2001	ROTHBERG and BADER		
	A40.	WO0127326	04/19/2001	EGHOLM and CHEN		
	A41.	WO0127327	04/19/2001	BRENNAN and CHATELAIN		
	A42.	WO0127329	04/19/2001	MACLEOD and ALDAZ		
	A43.					
	A44.					

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
S	A45.	ANDERSON et al., Pharmacogenetics., 2(1):25-31 (1992)	
	A46.	BALIAN et al., Clin. Pharmacol. Ther., 57(6):662-669 (1995)	
	A47.	BERTILSSON, Clin. Pharmacokin., 29(3):192-209 (1995)	
	A48.	CHANG et al., Br. J. clin. Pharmac., 39:511-518 (1995)	
	A49.	EVANS et al., Pharmacogenetics, 5(2):64-71 (1995)	
	A50.	GOLDSTEIN et al., Biochemistry, 33(7):1743-1752 (1994)	
	A51.	GOLDSTEIN et al., Pharmacogenetics, 7(1):59-64 (1997)	
	A52.	GOLDSTEIN, Br. J. clin. Pharmac., 52:349-355 (2001)	
	A53.	IBEANU et al., J. Pharmacol. Exp. Ther., 290(2):635-640 (1999)	
	A54.	IEIRI et al., Clin. Pharmacol. Ther., 59(6):647-653 (1996)	
	A55.	MACAULAY et al., Science, 308:1034-1036 (2005)	
	A56.	MEYER and ZANGER, Annu. Rev. Pharmacol. Toxicol., 37:269-296 (1997)	
	A57.	RICHARDS et al, Am. J. Hum. Genet. 87:1251-1276 (2000)	
	A58.	TANAKA, J Clin Pharm Ther., 24:323-329 (1999)	
	A59.	WILKINSON et al., Pharmac. Ther. 43:53-76 (1989)	
	A60.	YIN et al., J. Clin. Pharmacol. 44:582-589 (2004)	
	A61.		
	A62.		

EXAMINER

DATE CONSIDERED

9/22/05

Substitute Disclosure Statement Form (PTO-1447)
 * EXAMINER: Initial if reference considered, whether or not provision is in conformance with MPEP 909. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional): Applicant is to place a check mark here if English language Translation is attached



Approved for use through 12/31/2000. Once 02/1/2001
US Patent & Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1418A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

Complete if Known

Application Number	09/943,531
Filing Date	08/30/2001
First Named Inventor	RISINGER
Group Art Unit	1634
Examiner Name	SAKELARIS, SALLY A

Sheet 1 of 3

Attorney Docket No: SGL-2020-UT

US PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
<i>[Handwritten Signature]</i>	A1.	4,656,127	04/07/1987	MUNDY	
	A2.	4,683,195	07/28/1987	MULLIS and ERLICH	
	A3.	4,683,202	07/28/1987	MULLIS	
	A4.	4,851,331	07/25/1989	VARY and DIAMOND	
	A5.	4,965,188	10/23/1990	MULLIS and ERLICH	
	A6.	5,547,835	08/20/1996	KOESTER	
	A7.	5,605,798	02/25/1997	KOESTER	
	A8.	5,679,524	10/21/1997	NIKIFOROV and KARN	
	A9.	5,691,141	11/25/1997	KOESTER	
	A10.	5,834,189	11/10/1998	STEVENS and DUNN	
	A11.	5,849,542	12/15/1998	REEVE and HOWE	
	A12.	5,851,770	12/22/1998	BABON and YOUIL	
	A13.	5,869,242	02/09/1998	KAMB	
	A14.	5,876,934	03/02/1999	DUTHIE and SEVIGNY	
	A15.	5,891,625	04/06/1999	BUCHARDT and EGHOLM	
	A16.	5,908,755	06/01/1999	KUMAR and HEANEY	
	A17.	5,912,118	06/15/1999	ANSORGE and VOSS	
	A18.	5,928,906	07/27/1999	KOESTER and VAN DEN BOOM	
	A19.	5,952,174	09/14/1999	NIKIFOROV and KARN	
	A20.	5,958,692	09/28/1999	COTTON and YOUIL	


EXAMINER

DATE CONSIDERED

9/22/05

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO
**INFORMATION DISCLOSURE
 STATEMENT BY APPLICANT**
 (Use as many sheets as necessary)



PTO/USPOA/28-021
 Approved for use through 07/01/2008, OAG 0651-0021
 US Patent & Trademark Office, U.S. DEPARTMENT OF COMMERCE
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OAG control number.

Complete if Known

Application Number	09/943,531
Filing Date	08/30/2001
First Named Inventor	RISINGER
Group Art Unit	1634
Examiner Name	SAKELARIS, SALLY A
Attorney Docket No: SGL-2020-UT	

Sheet 2 of 3

US PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
48	A21.	5,976,802	11/02/1999	ANSORGE and VOSS	
	A22.	5,981,186	11/09/1999	GABE and GILCHRIST	
	A23.	5,998,143	12/07/1999	ELLIS and DODGE	
	A24.	6,004,744	12/21/1999	GOELET and KNAPP	
	A25.	6,013,431	01/11/2000	SOEDERLUND and SYVANEN	
	A26.	6,013,499	01/11/2000	NARUMIYA and IWAMATSU	
	A27.	6,017,702	01/25/2000	LEE and ROSENBLUM	
	A28.	6,043,031	03/28/2000	KOESTER and HIGGENS	
	A29.	6,046,005	04/04/2000	JU and KONRAD	
	A30.	6,087,095	07/11/2000	ROSENTHAL and BRENNER	
	A31.	6,110,684	08/29/2000	KEMPER and BIRKENKAMP-DEMTROEDER	
	A32.	6,183,958	02/06/2001	STANTON	
	A33.	6,194,144	02/27/2001	KOESTER	
	A34.	6,210,891	04/03/2001	NYREN and UHLEN	
	A35.	6,229,911	05/08/2001	BALABAN and AGGARWAL	
	A36.				
	A37.				
	A38.				

FOREIGN PATENT DOCUMENTS

EXAMINER

DATE CONSIDERED

9/22/05

Substitute Disclosure Statement Form (PTO-1449)
 * EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO
**INFORMATION DISCLOSURE
 STATEMENT BY APPLICANT**
 (Use as many sheets as necessary)

AUG 10 2005
 PAT. & TRADEMARK OFFICE

Under the Payment Reduction Act of 1985, no papers are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A(7-02)
 Approved for use through 07/31/2005. OMB 0351-0001
 US Patent & Trademark Office, U.S. DEPARTMENT OF COMMERCE

Complete if Known

Application Number 09/943,531
 Filing Date 08/30/2001
 First Named Inventor RISINGER
 Group Art Unit 1634
 Examiner Name SAKELARIS, SALLY A

Sheet 3 of 3

Attorney Docket No: SGL-2020-UT

Examiner Initials*	Cite No.	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ¹
SA	A39.	WO0120039	03/22/2001	ROTHBERG and BADER		
	A40.	WO0127326	04/19/2001	EGHOLM and CHEN		
	A41.	WO0127327	04/19/2001	BRENNAN and CHATELAIN		
SA	A42.	WO0127329	04/19/2001	MACLEOD and ALDAZ		
	A43.					
	A44.					

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
SA	A45.	ANDERSON et al., Pharmacogenetics,, 2(1):25-31 (1992)	
	A46.	BALIAN et al., Clin. Pharmacol. Ther., 57(6):662-669 (1995)	
	A47.	BERTILSSON, Clin. Pharmacokinet., 29(3):192-209 (1995)	
	A48.	CHANG et al., Br. J. clin. Pharmac., 39:511-518 (1995)	
	A49.	EVANS et al., Pharmacogenetics, 5(2):64-71 (1995)	
	A50.	GOLDSTEIN et al., Biochemistry, 33(7):1743-1752 (1994)	
	A51.	GOLDSTEIN et al., Pharmacogenetics, 7(1):59-64 (1997)	
	A52.	GOLDSTEIN, Br. J. clin. Pharmac., 52:349-355 (2001)	
	A53.	IBEANU et al, J. Pharmacol. Exp. Ther., 290(2):835-840 (1999)	
	A54.	IEIRI et al., Clin. Pharmacol. Ther., 59(6):647-653 (1996)	
HA	A55.	MACAULAY et al., Science, 308:1034-1036 (2005)	
	A56.	MEYER and ZANGER, Annu. Rev. Pharmacol. Toxicol., 37:269-296 (1997)	
	A57.	RICHARDS et al, Am. J. Hum. Genet. 67:1251-1276 (2000)	
	A58.	TANAKA, J Clin Pharm Ther., 24:323-329 (1999)	
	A59.	WILKINSON et al., Pharmac. Ther. 43:53-76 (1989)	
	A60.	YIN et al., J. Clin. Pharmacol. 44:582-589 (2004)	
	A61.		
	A62.		

EXAMINER

DATE CONSIDERED

9/22/05

Substitute Disclosure Statement Form (PTO-1449)
 *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 909. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.